Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 May;58(5):1476–1478. doi: 10.1128/iai.58.5.1476-1478.1990

Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.

R F Hector 1, E Yee 1, M S Collins 1
PMCID: PMC258651  PMID: 2323826

Abstract

Mouse models of systemic candidiasis and pulmonary and systemic aspergillosis were established by using DBA/2N mice, which are known to be deficient in the C5 component of complement. In experiments comparing lethality in the respective models in DBA/2N versus outbred CFW mice, results showed that the 50% lethal dose values for the DBA/2N mice were 10- to 1,000-fold lower than those for the outbred mice, depending on the experiment. Additionally, onset of death was somewhat delayed for the DBA/2N mice. In the case of the pulmonary aspergillosis model, administration of cortisone acetate was necessary to ensure lethality after intranasal infection, but only a single dose was necessary.

Full text

PDF
1476

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADRIANO S. M., SCHWARZ J. Experimental moniliasis in mice. Am J Pathol. 1955 Sep-Oct;31(5):859–873. [PMC free article] [PubMed] [Google Scholar]
  2. Dixon D. M., Polak A., Walsh T. J. Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun. 1989 May;57(5):1452–1456. doi: 10.1128/iai.57.5.1452-1456.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eilam Y., Polacheck I., Ben-Gigi G., Chernichovsky D. Activity of phenothiazines against medically important yeasts. Antimicrob Agents Chemother. 1987 May;31(5):834–836. doi: 10.1128/aac.31.5.834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Graybill J. R., Ahrens J. Itraconazole treatment of murine aspergillosis. Sabouraudia. 1985 Jun;23(3):219–223. doi: 10.1080/00362178585380321. [DOI] [PubMed] [Google Scholar]
  5. Guentzel M. N., Herrera C. Effects of compromising agents on candidosis in mice with persistent infections initiated in infancy. Infect Immun. 1982 Jan;35(1):222–228. doi: 10.1128/iai.35.1.222-228.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hector R. F., Domer J. E., Carrow E. W. Immune responses to Candida albicans in genetically distinct mice. Infect Immun. 1982 Dec;38(3):1020–1028. doi: 10.1128/iai.38.3.1020-1028.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hector R. F., Yee E. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother. 1990 Mar;34(3):448–454. doi: 10.1128/aac.34.3.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jevons S., Gymer G. E., Brammer K. W., Cox D. A., Leeming M. R. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979 Apr;15(4):597–602. doi: 10.1128/aac.15.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kisch A. L., Maydew R. P., Evan A. P. Synergistic nephrotoxicity of amphotericin B and cortisone acetate in mice. J Infect Dis. 1978 Jun;137(6):789–794. doi: 10.1093/infdis/137.6.789. [DOI] [PubMed] [Google Scholar]
  10. Lyon F. L., Hector R. F., Domer J. E. Innate and acquired immune responses against Candida albicans in congenic B10.D2 mice with deficiency of the C5 complement component. J Med Vet Mycol. 1986 Oct;24(5):359–367. doi: 10.1080/02681218680000551. [DOI] [PubMed] [Google Scholar]
  11. PIGGOTT W. R., EMMONS C. W. Device for inhalation exposure of animals to spores. Proc Soc Exp Biol Med. 1960 Apr;103:805–806. doi: 10.3181/00379727-103-25677. [DOI] [PubMed] [Google Scholar]
  12. Rhodes J. C. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia. 1985 Jun;23(3):225–234. doi: 10.1080/00362178585380331. [DOI] [PubMed] [Google Scholar]
  13. SIDRANSKY H., FRIEDMAN L. The effect of cortisone and antibiotic agents on experimental pulmonary aspergillosis. Am J Pathol. 1959 Jan-Feb;35(1):169–183. [PMC free article] [PubMed] [Google Scholar]
  14. Schaffner A., Douglas H., Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest. 1982 Mar;69(3):617–631. doi: 10.1172/JCI110489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Scott V. R., Boehme R., Matthews T. R. New class of antifungal agents: jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis species. Antimicrob Agents Chemother. 1988 Aug;32(8):1154–1157. doi: 10.1128/aac.32.8.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES